로그인
토토사이트
먹튀사이트/제보
업체홍보/구인
신규사이트
지식/노하우
놀이터홍보
판매의뢰
스포츠분석
뉴스
후기내역공유
커뮤니티
포토
포인트
보증업체
카지노 먹튀
토토 먹튀
먹튀제보
구인
구직
총판
제작업체홍보
카지노
토토
홀덤
카지노 노하우
토토 노하우
홀덤 노하우
기타 지식/노하우
유용한 사이트
토토 홍보
카지노 홍보
홀덤 홍보
꽁머니홍보
신규가입머니
제작판매
제작의뢰
게임
축구
야구
농구
배구
하키
미식축구
스포츠뉴스
연예뉴스
IT뉴스
카지노 후기
토토 후기
홀덤 후기
자유게시판
유머★이슈
동영상
연예인
섹시bj
안구정화
출석하기
포인트 랭킹
포인트 마켓
로그인
자동로그인
회원가입
정보찾기
뉴스
더보기
[]
강아지 산책부터 벌레 퇴치까지… 2040은 ‘초미니 알바’ 중
N
[]
단지 안에 아이스링크-풀빌라… “차별화 전략” vs “비용만 높여”
N
[]
국힘 “판결엔 불복, 대법원장엔 보복” 릴레이 장외투쟁 여론전
N
[]
어설픈 부켈레 따라하기?…콜롬비아 대통령 '과시형 통치' 논란
N
[]
[단독]숨진 LEET 만점자 1, 2교시 시험지 보관 안돼… 3교시 논술형은 안 치러
N
커뮤니티
더보기
[유머★이슈]
바란 은퇴보다 더 소름돋는점
[유머★이슈]
오늘 국군의날 예행연습에 최초 공개된 장비들
[유머★이슈]
손흥민이 한국 병역 시스템에 영향 끼친 것.
[유머★이슈]
시댁의 속터지는 스무고개식 대화법
[유머★이슈]
엄마. 나 여자 임신시켜버렸어
목록
글쓰기
[IT뉴스]Orum Loses Sole Clinical Asset After BMS Return[K-Bio Pulse]
온카뱅크관리자
조회:
79
2026-09-19 07:47:25
<div class="article_view" data-translation-body="true" data-tiara-layer="article_body" data-tiara-action-name="본문이미지확대_클릭"> <section dmcf-sid="pds4LsAirc"> <div contents-hash="3af5a8ce1d7dffdb0745e821b063f2489c03dcf4688b5644f4344dc48d77dfb9" dmcf-pid="UJO8oOcnsA" dmcf-ptype="general"> <div> This article was released as <strong>Pharm Edaily Premium Content</strong> on September 18, 2026, at 7:40 AM. </div> </div> <p contents-hash="8cac8cd0c387aa84d3af804390f66dab4ca78639ec5dd7d34d85761b1d977351" dmcf-pid="uiI6gIkLmj" dmcf-ptype="general">[Jiwan Kim, Edaily Reporter] Biotech stocks moved in sharply different directions on Sept. 17 as investors reacted to corporate restructuring and drug development updates.</p> <p contents-hash="52d3787c71b7416c9724630b14c28bc98c58ee103fbf317c01fa7e47001c3c10" dmcf-pid="7nCPaCEoON" dmcf-ptype="general">Orum Therapeutics plunged more than 33% in after-hours trading after Bristol Myers Squibb (BMS) discontinued development of blood cancer candidate ORM-6151 and returned the rights to the company. In contrast, Oscotec rose 8.59% after forming a special committee to pursue the full acquisition of Genosco, while AriBio gained 5.59% on plans to invest KRW 18 billion in AriBioLab together with AriBio Holdings.</p> <p contents-hash="f0b845fb13c612d6b481c8457aaf1a4d7b5f00f0c8c199c0806a266b03e9ddf0" dmcf-pid="zUMXqMV7ra" dmcf-ptype="general"><strong>Orum plunges after BMS returns ORM-6151</strong></p> <p contents-hash="ecb29bad42aea5c1a0d5c9d20727c8329ef5b47a4ffc0c9ac1e928178cbdd0ff" dmcf-pid="quRZBRfzsg" dmcf-ptype="general">BMS has discontinued development of ORM-6151, a blood cancer candidate licensed from Orum Therapeutics, and returned the rights to the Korean biotech company.</p> <p contents-hash="88aa4978732defb11e72a9d015fb7d9e99cd9ae3ce1cc540a6ccef8beea0b709" dmcf-pid="B7e5be4qIo" dmcf-ptype="general">ORM-6151 was Orum Therapeutics’ only clinical-stage asset. BMS had been conducting a Phase 1 study in the United States, Europe and Canada for acute myeloid leukemia and myelodysplastic syndromes, including monotherapy and combination treatment with azacitidine and venetoclax.</p> <figure class="s_img figure_frm origin_fig" contents-hash="f43a566bf036a279ac5c0be4975970dc82e3c7e0861149ed58dec014963d3908" dmcf-pid="bzd1Kd8BsL" dmcf-ptype="figure"> <p class="link_figure"><img alt="Orum Loses Sole Clinical Asset After BMS Return[K-Bio Pulse]" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202609/19/Edaily/20260919074352599kdrl.png" data-org-width="220" dmcf-mid="FdrVirNdID" dmcf-mtype="image" height="auto" src="https://img3.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202609/19/Edaily/20260919074352599kdrl.png" width="220"></p> <figcaption class="txt_caption default_figure"> Orum Loses Sole Clinical Asset After BMS Return[K-Bio Pulse] </figcaption> </figure> <p contents-hash="6b7534a0603fd1a64e2f97def8175f7799b8b0a17a50105d758dd17b1012d50f" dmcf-pid="KqJt9J6bIn" dmcf-ptype="general">Following the news, Orum Therapeutics traded at KRW 35,500 at 6:02 p.m. in after-hours trading, down 33.52% from its regular-session close of KRW 53,400.</p> <p contents-hash="39d56c95bd26aa92232dc0cb0d17b223630a1f5f858a50ed8b15885b3a0c4300" dmcf-pid="9BiF2iPKmi" dmcf-ptype="general">The termination eliminates about $80 million in remaining development milestone payments, although Orum Therapeutics will retain the $100 million upfront payment received under the 2023 licensing deal.</p> <p contents-hash="80901796540c7b66cf11b9b823c76ddf26c74ec14255da4a45641ee40252510d" dmcf-pid="2bn3VnQ9sJ" dmcf-ptype="general">The return also leaves Orum Therapeutics without a clinical-stage pipeline. The company plans to advance another DAC candidate, ORM-1153, into clinical development by the end of next year.</p> <p contents-hash="1cd3159085aa3bbfc03ac019b313c17039f339e7673d8143328f12daaad77562" dmcf-pid="VKL0fLx2rd" dmcf-ptype="general">Orum Therapeutics had previously halted development of ORM-5029, a HER2-targeting DAC candidate, after serious adverse events, including a death, were reported in a Phase 1 study in 2024.</p> <p contents-hash="0f340059ebc1e48d4054fd201ccf55769c67c3e747bf5b91167a76c3350fecf5" dmcf-pid="f9op4oMVwe" dmcf-ptype="general">With both ORM-5029 and ORM-6151 discontinued, future clinical data from candidates such as ORM-1153 will be important in demonstrating the potential of the company’s DAC platform.</p> <p contents-hash="980fcd8c1c82890b93f6e05df5f55bd17d7743ae70fc495b9fc8a2726123c93f" dmcf-pid="4Vau6ae4mR" dmcf-ptype="general"><strong>Oscotec gains on Genosco acquisition plan</strong></p> <p contents-hash="ec0bbf61a50ad6223843f1304370871275c91e7aedccd2274f810c8902873976" dmcf-pid="8fN7PNd8EM" dmcf-ptype="general">Oscotec closed at KRW 37,300, up 8.59%, after announcing a special committee to pursue the acquisition of Genosco’s remaining shares.</p> <p contents-hash="b20924a5442aee549843476e8d36a53bdf3a4a90d67435d6d11d877937968c37" dmcf-pid="64jzQjJ6Ix" dmcf-ptype="general">Oscotec currently owns 59.31% of U.S.-based Genosco, which helped develop lazertinib, the original compound behind the FDA-approved lung cancer drug Lazcluze.</p> <figure class="figure_frm origin_fig" contents-hash="c465fd9c0457dc0d243196bc1443603b5819fa546184456ebfa6fb1e3d5e922d" dmcf-pid="P8AqxAiPsQ" dmcf-ptype="figure"> <p class="link_figure"><img alt="Yoon Tae-young, CEO of Oscotec. (Photo by Kim Jin-soo)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202609/19/Edaily/20260919074353889onkz.jpg" data-org-width="1280" dmcf-mid="3Td1Kd8BrE" dmcf-mtype="image" height="auto" src="https://img1.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202609/19/Edaily/20260919074353889onkz.jpg" width="658"></p> <figcaption class="txt_caption default_figure"> Yoon Tae-young, CEO of Oscotec. (Photo by Kim Jin-soo) </figcaption> </figure> <p contents-hash="dbfbf199f705520f958101ac6d43eb5ccf9069a9f2ff67921fd38106aae2982d" dmcf-pid="Q6cBMcnQOP" dmcf-ptype="general">The committee will review potential conflicts of interest, select external valuation firms and assess key issues related to the acquisition. Oscotec is also considering valuations from multiple outside institutions.</p> <p contents-hash="50ba0752039fbb98ca926992fff03244aae2073f4a49073534348e9b6f80c0ab" dmcf-pid="xPkbRkLxr6" dmcf-ptype="general">After the valuation process, the company plans to negotiate with Genosco’s minority shareholders and determine the final transaction structure and financing plan. It may also bring in strategic or financial investors to limit financial pressure on existing shareholders.</p> <p contents-hash="c383c39a16dca88bc406c2b4463acec248fefdd5b7a38f7c335a2525040d48b3" dmcf-pid="yv7rY71yE8" dmcf-ptype="general"><strong>AriBio rises on KRW 18 billion investment</strong></p> <p contents-hash="76c60954701c5ae601a7651bfa51d9c5839c745d5645774a8c8648e19c61e9e9" dmcf-pid="WTzmGztWO4" dmcf-ptype="general">AriBio and AriBio Holdings will invest KRW 15 billion and KRW 3 billion, respectively, in AriBioLab through a third-party share offering.</p> <p contents-hash="5014d629f68723fabb3f167321e26faa729dfc7132acc3a740a863e59195e875" dmcf-pid="YyqsHqFYwf" dmcf-ptype="general">After the transaction, AriBio will hold a 15.9% stake and become AriBioLab’s largest shareholder, while AriBio Holdings will own 14.1%. Their combined stake will reach 30%.</p> <figure class="figure_frm origin_fig" contents-hash="fa5e1ef5a3b46fcb05df7632838cf31e95b29f603700eaaeb284bda39e83d9ab" dmcf-pid="GH9h19UZEV" dmcf-ptype="figure"> <p class="link_figure"><img alt="Fred Kim, head of AriBio’s U.S. operations, speaks on “The Global Clinical Development Journey and Commercialization Strategy for AR1001, an Oral Alzheimer’s Disease Treatment,” at the Edaily K-Bio Deal Summit 2026 held at KG Harmony Hall in Sunhwa-dong, Jung-gu, Seoul, on Sept. 9. (Photo by Lee Young-hoon)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202609/19/Edaily/20260919074355153dxpw.jpg" data-org-width="1280" dmcf-mid="0In3VnQ9rk" dmcf-mtype="image" height="auto" src="https://img4.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202609/19/Edaily/20260919074355153dxpw.jpg" width="658"></p> <figcaption class="txt_caption default_figure"> Fred Kim, head of AriBio’s U.S. operations, speaks on “The Global Clinical Development Journey and Commercialization Strategy for AR1001, an Oral Alzheimer’s Disease Treatment,” at the Edaily K-Bio Deal Summit 2026 held at KG Harmony Hall in Sunhwa-dong, Jung-gu, Seoul, on Sept. 9. (Photo by Lee Young-hoon) </figcaption> </figure> <p contents-hash="108f8dc2c12d2ed2fe982a001e1e899340769a3a59eabc377bca5e119b703327" dmcf-pid="HX2lt2u5D2" dmcf-ptype="general">AriBio is conducting global Phase 3 trials of AR1001, an oral Alzheimer’s disease treatment candidate, while AriBioLab is developing vaccines and immunotherapies based on its proprietary immune-adjuvant platforms.</p> <p contents-hash="ffdec0b1d462e7848e81ebc09fbbc160a7876af737ed7322b3a83d66a818f7c8" dmcf-pid="XZVSFV71E9" dmcf-ptype="general">AriBioLab’s pipeline includes Phase 2 shingles vaccine candidate CVI-VZV-001 and mRNA-LNP-based immuno-oncology candidate CTRNA-001.</p> <p contents-hash="f19387e2b55f0b25be207ea14e294a691aaadaec3284b6c34a28ee866cda3ee1" dmcf-pid="Z5fv3fztOK" dmcf-ptype="general">The companies have also begun jointly developing an Alzheimer’s vaccine, with the latest investment expected to strengthen cooperation across Alzheimer’s therapies, vaccines and immuno-oncology.</p> <p contents-hash="c1f43b42c510d8f122e8d87a84fc9b30fe4d647d8597465859ddaa4905c9e46b" dmcf-pid="514T04qFwb" dmcf-ptype="general">김지완 (2pac@edaily.co.kr) </p> </section> </div> <p class="" data-translation="true">Copyright © 이데일리. 무단전재 및 재배포 금지.</p>
댓글등록
댓글 총
0
개
맨위로
이번주
포인트
랭킹
매주 일요일 밤 0시에 랭킹을 초기화합니다.
1
4,000
상품권
2
3,000
상품권
3
2,000
상품권
업체홍보/구인
더보기
[구인]
유투브 BJ 구인중이자나!완전 럭키비키자나!
[구인]
에카벳에서 최대 조건으로 부본사 및 회원님들 모집합니다
[구인]
카지노 1번 총판 코드 내립니다.
[구인]
어느날 부본사 총판 파트너 모집합니다.
[구인]
고액전용 카지노 / 헬렌카지노 파트너 개인 팀 단위 모집중 최고우대
놀이터홍보
더보기
[홀덤 홍보]
텍사스홀덤 핸드 순위- 홀카드의 가치
[홀덤 홍보]
텍사스홀덤 핸드 순위 - 프리플랍(Pre-Flop) 핸드 랭킹
[토토 홍보]
미니게임개발제작 전문업체 포유소프트를 추천드립니다.
[토토 홍보]
2023년 일본 만화 판매량 순위 공개
[토토 홍보]
무료만화 사이트 보는곳 3가지 추천
지식/노하우
더보기
[카지노 노하우]
혜택 트렌드 변화 위험성 다시 가늠해 보기
[카지노 노하우]
호기심이 부른 화 종목 선택의 중요성
[카지노 노하우]
카지노 블랙잭 카드 조합으로 히트와 스탠드를 결정하는 방법
[카지노 노하우]
흥부가 놀부될때까지 7
[카지노 노하우]
5월 마틴하면서 느낀점
판매의뢰
더보기
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
포토
더보기
채팅하기